הבדלים בין גרסאות בדף "טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table - urine cultures"
מתוך ויקירפואה
מ (Motyk העביר את הדף טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table – urine cultures לשם טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table - urine cultures) |
|||
(גרסת ביניים אחת של אותו משתמש אינה מוצגת) |
גרסה אחרונה מ־09:32, 9 בדצמבר 2022
שימוש מושכל באנטיביוטיקה ונהלים למניעת זיהומים
מאת המרכז הרפואי שערי צדק: פרופ' עמוס ינון, פרופ' יחיאל שלזינגר, ד"ר דוד רווה
שם הספר: שימוש מושכל באנטיביוטיקה ונהלים למניעת זיהומים | |
---|---|
![]() | |
שם המחבר | פרופ' עמוס ינון, פרופ' יחיאל שלזינגר, דר' דוד רווה |
שם הפרק | טבלאות רגישויות מבית החולים שערי צדק - תרביות שתן - Shaare zedek medical center antibiotic sensitivity table - urine cultures |
מוציא לאור | |
מועד הוצאה | תשע"א – 2010 |
מספר עמודים | 196 |
הקדשה | ספר זה מוקדש לפרופ' חיים הרשקו בהוקרה עמוקה |
Table 12: Urine cultures
Table 12a: Urine cultures, main isolates, by source of patients (2001-2008)
Isolated organism | ≤48 hours in hospital
N=21833 |
>48 hours in hospital
N=9823 |
p |
---|---|---|---|
Acinetobacter | 237 (1) | 585 (6) | <0.001 |
Enterobacteriaceae (total) | 15323 (70) | 5397 (55) | <0.001 |
Citrobacter koserii | 499 (2) | 174 (2) | |
Enterobacter cloacae | 411 (2) | 312 (3) | |
E.coli | 8853 (40) | 1927 (20) | <0.001 |
Klebsiella pneumoniae | 2132 (10) | 1371 (14) | <0.001 |
Morganella morganii | 360 (2) | 192 (2) | |
Proteus mirabilis | 1640 (7) | 762 (8) | <0.01 |
Providencia stuartii | 196 | 131 | |
Serratia marcescens | 77 | 52 | |
Enterococcus sp. | 2467 (11) | 1833 (19) | <0.001 |
Pseudomonas aeruginosa | 1404 (6) | 1263 (13) | <0.001 |
Staphylococcus aureus | 394 (1) | 107 (1) | |
Staphylococcus epidermidis | 686 (3) | 309 (3) | |
Streptococcus | 707 (3) | 123 (1) | <0.001 |
Group A | 22 | 4 | |
Group B | 394 (2) | 50 (0.5) | <0.001 |
Group D | 90 | 24 | |
Group G | 12 | 3 | |
S.viridans | 122 | 15 |
Table 12b: Antimicrobial susceptibilities (%) of Enterobacteriaceae isolated from urine cultures, 2000-2008
N |
≤48 hrs in hospital[1]
15316 |
>48 hours in hospital[1]
5397 |
---|---|---|
Penicillins | ||
Augmentin | 65 | 51 |
Tazocin | 92 | 82 |
Cephalosporins | ||
Cefazolin | 63 | 43 |
Cefuroxime | 76 | 56 |
Ceftriaxone | 84 | 66 |
Ceftazidime | 84 | 67 |
Cefepime | 86 | 69 |
Carbapenems | ||
Ertapenem | 99 | 96 |
Imipenem | 99 | 98 |
Aminoglycosides | ||
Gentamicin | 85 | 69 |
Amikacin | 98 | 94 |
Other | ||
Chloramphenicol | 78 | 62 |
Cotrimoxazole | 62 | 52 |
Ciprofloxacin[2] | 76 | 60 |
Colistin | 84 | 77 |
Nitrofurantoin | 70 | 52 |
ESBL (Extended Spectrum Beta-Lactamase) - positive[3] | 15 | 32 |
Table 12c: Antimicrobial susceptibilities (%) of Pseudomonas aeruginosa isolated from urine cultures, 2001-2008
≤48 hrs in hospital[4] | >48 hours in hospital[4] | |
---|---|---|
Penicillins | ||
Mezlocillin[4] | 77 | 73 |
Tazocin | 92 | 88 |
Cephalosporins | ||
Ceftazidime | 92 | 89 |
Cefepime[5] | 95 | 94 |
Carbapenems | ||
Imipenem | 94 | 91 |
Meropenem[6] | 94 | 93 |
Aminoglycosides | ||
Gentamicin | 84 | 81 |
Amikacin | 94 | 93 |
Other | ||
Ciprofloxacin | 73 | 69 |
Colistin | 100 | 100 |
Table 12d: Ten most frequently isolated organisms from urine cultures and risk of isolation in presence and absence of urinary catheter (1st trimesters, 1990-2000)
No. | Organism | Isolates
(n=5272) n (%) |
Catheter | RR[7]
(95% CI) |
P
value | |
---|---|---|---|---|---|---|
Absent
(n=3421) n (%) |
Present
(n=1851) n (%) | |||||
1 | Escherichia coli | 2540 (48) | 1822 (53) | 718 (39) | 0.73 (0.69-0.78) | <0.001 |
2 | Klebsiella pneumoniae | 574 (11) | 340 (10) | 234 (13) | 1.28 (1.09-1.49) | 0.002 |
3 | Pseudomonas aeruginosa | 469 (9) | 259 (8) | 210 (11) | 1.50 (1.27-1.79) | <0.001 |
4 | Enterococcus spp. | 418 (8) | 198 (6) | 220 (12) | 2.06 (1.72-2.47) | <0.001 |
5 | Proteus mirabilis | 333 (6) | 207 (6) | 126 (7) | 1.13 (0.91-1.40) | 0.265 |
6 | Staphylococcus coag (-) | 173 (3) | 124 (4) | 49 (3) | 0.73 (0.53-1.01) | 0.06 |
7 | Enterobacter cloacae | 129 (2) | 75 (2) | 54 (3) | 1.34 (0.95-1.89) | 0.099 |
8 | Acinetobacter baumanii | 88 (2) | 48 (1) | 40 (2) | 1.55 (1.02-2.34) | 0.04 |
9 | Citrobacter freundii | 72 (1) | 46 (1) | 26 (1) | 1.05 (0.65-1.69) | 0.846 |
10 | Staphylococcus aureus | 61 (1) | 37 (1) | 24 (1) | 1.20 (0.72-2.00) | 0.477 |
Total | 4857 (92) | 3156 (92) | 1701 (92) |
Table 12e: Frequencies of isolation of selected Enterobacteriaceae, Pseudomonas and Enterococcus, according to source of patient (2001-2008).
Organism | Total
n (%) |
Emergency Department
n (%) |
Hospital Departments
n (%) |
RR (95% CI)[8] | P value |
---|---|---|---|---|---|
Enterobacteriaceae | 3802 (72) | 1586 (82) | 2216 (66) | 1.25 (1.21-1.29) | <0.001 |
Other organisms | 1470 (28) | 337 (18) | 1133 (34) | 0.52 (0.47-0.58) | <0.001 |
Escherichia coli | 2508 (48) | 1219 (63) | 1289 (38) | 1.65 (1.56-1.74) | <0.001 |
Pseudomonas | 469 (9) | 109 (6) | 360 (11) | 0.53 (0.43-0.65) | <0.001 |
Enterococcus spp. | 418 (8) | 63 (3) | 355 (11) | 0.31 (0.24-0.40) | <0.001 |
All Isolates | 5272 | 1923 | 3349 |
הערות שוליים
- ↑ 1.0 1.1 Differences in rates of susceptibility between community and hospital acquired strains were significant for all antimicrobials (p<0.001).
- ↑ No significant changes in susceptibility % were noted over the study period.
- ↑ ESBL: extended spectrum beta-lactamase
- ↑ 4.0 4.1 4.2 continues to be tested
- ↑ tested until 2006
- ↑ tested since 2006
- ↑ Relative risk of organism isolation in the presence versus absence of a catheter.
- ↑ Relative risk of organism isolation in emergency department versus inpatient departments.
ביבליוגרפיה
- Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis 2003; 22(3):158-64.
- Raveh D, Rosenzweig I, Rudensky B, Yinnon AM. Prospective, case control study to determine risk factors for community-acquired urinary tract infection due to Pseudomonas aeruginosa or Enterococcus. Eur J Clin Microbiol Infect Dis 2006; 25: 331-334.
- Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis 2003 Mar; 22(3):158-64.